July 9: A look at five Indian pharmaceutical companies strengthening their international footprint through exports, manufacturing expansion, regulatory approvals, and global market access.
India’s pharmaceutical industry continues to play a critical role in global healthcare by supplying affordable, high-quality medicines to countries across developed and emerging markets. From generic formulations and active pharmaceutical ingredients to specialty therapies and contract manufacturing services, Indian pharmaceutical companies have built a strong reputation for quality, scale, and regulatory compliance.
With pharmaceutical exports reaching US$30.47 billion in FY25, Indian companies are steadily expanding their international footprint through manufacturing investments, product innovation, regulatory approvals, and entry into new markets. The following companies illustrate how India’s pharmaceutical sector continues to strengthen its presence across global markets.
Unichem Laboratories Limited
Unichem Laboratories has established a growing presence across international markets through its subsidiaries, partnerships, and regulatory-approved product portfolio. The company operates in key markets including the United States, Canada, Brazil, and other Latin American countries. Through its wholly owned subsidiaries and strategic alliances, Unichem markets generic pharmaceutical products while continuing to develop a pipeline of APIs and abbreviated new drug applications for regulated markets. The company’s manufacturing facilities have received approvals from international regulatory agencies including the US FDA, UK MHRA, ANVISA Brazil, PMDA Japan, and EU GMP authorities, supporting its global expansion strategy.
HAB Pharmaceuticals & Research Limited
HAB Pharmaceuticals and Research Limited is strengthening its export presence through continued investments in manufacturing capacity and international market development. Hab Pharma Selaqui supplies pharmaceutical products across multiple overseas markets like Afghanistan, Kenya, UAE, Japan, Nigeria, Turkey, Egypt, Tanzania, Iraq, Yemen, Mauritius, Somalia, Indonesia, etc. and continues to expand its production capabilities through investments in sterile and oral solid dosage manufacturing facilities. With a focus on quality manufacturing, product diversification, and export-led growth, HAB Pharma is steadily enhancing its role within India’s pharmaceutical export ecosystem and supporting access to affordable medicines across international markets.
Viyash Scientific Limited has built a strong international footprint in the animal health sector and today operates across more than 100 countries through its veterinary formulations and API business. The company maintains manufacturing facilities in India, Spain, Brazil, and Turkey, with approvals from international regulatory bodies including the US FDA, EU GMP, WHO, and TGA. Through its focus on animal healthcare, global manufacturing network, and regulated-market capabilities, Sequent continues to strengthen its position as a global veterinary pharmaceutical company.
Medicamen Biotech Limited
Medicamen Biotech has accelerated its global expansion through a series of regulatory milestones and manufacturing upgrades. The company’s Bhiwadi manufacturing facility recently secured European Union Good Manufacturing Practice certification, while its parent company, Shivalik Rasayan, received US FDA approval for its API manufacturing facility. Medicamen has also announced US FDA approval for its sterile oncology manufacturing facility, strengthening its ability to serve regulated international markets. These approvals position the company to expand its presence across key global pharmaceutical markets while supporting future export growth.
Beta Drugs Ltd.
Beta Drugs has emerged as a specialized oncology pharmaceutical company focused on improving access to affordable cancer therapies. The company has developed a strong portfolio of oncology formulations and continues to invest in manufacturing capabilities that support domestic and international growth to Latin America, Asia & Southeast Asia, Middle East & Africa, etc. By focusing on quality standards, product innovation, and specialized oncology therapies, Beta Drugs is expanding its presence in global healthcare markets while contributing to broader access to cancer treatment solutions.
India’s Expanding Global Pharmaceutical Footprint
India’s pharmaceutical exporters continue to strengthen the country’s position as a trusted global supplier of medicines. As demand for affordable healthcare solutions grows worldwide, Indian companies are expanding their reach through manufacturing excellence, innovation, regulatory compliance, and strategic investments in international markets.
From established manufacturers to fast-growing specialty pharmaceutical companies, these organizations are helping reinforce India’s role as one of the world’s most important pharmaceutical supply hubs while supporting healthcare access across the world. Their continued investments in quality, capacity expansion, and international market development are expected to further strengthen India’s standing in the global pharmaceutical industry.